Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic TargetsNicola Antonio di Meo, Giuseppe Lucarelli, Francesco Lasorsa et al.|International Journal of Molecular Sciences|2022Cited by 190
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical PracticeFrancesco Lasorsa, Giuseppe Lucarelli, Matteo Ferro et al.|Biomedicines|2023Cited by 161
Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell CarcinomaFrancesco Lasorsa, Giuseppe Lucarelli, Monica Rutigliano et al.|Journal of Clinical Medicine|2023Cited by 129
Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell CarcinomaFrancesco Lasorsa, Giuseppe Lucarelli, Monica Rutigliano et al.|International Journal of Molecular Sciences|2023Cited by 98
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder CancerNicola Antonio di Meo, Giuseppe Lucarelli, Davide Loizzo et al.|International Journal of Molecular Sciences|2022Cited by 61